Oncology & Cancer

Ovarian cancer subtypes may predict response to bevacizumab

Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. Results of the research were presented today at the ...

page 2 from 2